Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development

(2017) Aaron R. Victor et al.   JOURNAL OF IMMUNOLOGY

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

(2017) Roberta Mazzone et al.   Clinical Epigenetics

Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers

(2016) Arash Salmaninejad et al.   IMMUNOLOGICAL INVESTIGATIONS

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

(2015) Keishi Adachi et al.   CANCER SCIENCE

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells

(2015) Fabien Gueugnon et al.   Oncotarget

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

(2014) A. Thomas et al.   CLINICAL CANCER RESEARCH

Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

(2013) I. Gojo et al.   CLINICAL CANCER RESEARCH

Reducing TNF Receptor 2 + Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients

(2013) Chindu Govindaraj et al.   CLINICAL CANCER RESEARCH

Natural killer cell deficiency

(2013) Jordan S. Orange   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

(2013) Shiguo Zhu et al.   PHARMACEUTICAL RESEARCH

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients

(2012) Michael J. Kelly-Sell et al.   AMERICAN JOURNAL OF HEMATOLOGY

HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression

(2012) Pierre-François Cartron et al.   Molecular Oncology

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma

(2011) Fabien Gueugnon et al.   AMERICAN JOURNAL OF PATHOLOGY

Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds

(2011) C. Blanquart et al.   CURRENT CANCER DRUG TARGETS

A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma

(2011) S. Leclercq et al.   EUROPEAN RESPIRATORY JOURNAL

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

(2009) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Epigenetics and cancer treatment

(2009) Lasse Sommer Kristensen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis and Modeling of New Benzofuranone Histone Deacetylase Inhibitors that Stimulate Tumor Suppressor Gene Expression

(2009) Cédric Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY